bg

Discovery 360

Everolimus versus alpelisib in higher level hormones receptor-positive breast that is HER2-negative focusing on different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications

Everolimus versus alpelisib in higher level hormones receptor-positive breast that is HER2-negative focusing on different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications Abstract Background The PI3K/AKT/mTORC1 axis is implicated in hormone receptor-positive HER2-negative metastatic breast cancer (HR+ HER2в€’ mBC) resistance to anti-estrogen treatments. Based on link between the BOLERO-2 trial, the mTORC1 inhibitor […]